Clinical Trials in Italy

• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus … Recruiting
  2024-520356-24-00 Phase II Refractory Metastatic Colorectal Cancer with Liver Dominant … Delcath Systems Inc.
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 Phase II/III Locally Advanced or Metastatic Urothelial Carcinoma Daiichi Sankyo Inc.
• Phase 2a Study of ALXN1920 in PMN Recruiting
  2025-520780-40-00 Phase II Primary Mebranous Nephropathy (PMN) Alexion Pharmaceuticals Inc.
• AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting
  2025-521707-48-00 Phase I KRAS Altered Advanced or Metastatic Solid Tumors Amgen Inc.
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting
  2025-521268-37-00 Phase IV Respiratory tract diseases Sanofi-Aventis Recherche & Developpement
• Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t… Recruiting
  2024-519479-24-00 Phase II metastatic colorectal cancer Fondazione GONO G.I.
• A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations… Recruiting
  2024-517102-29-00 Phase III Intestinal Malabsorption Elgan Pharma Ltd.
• A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy… Recruiting
  2025-521511-40-00 Phase II/III metastatic non-small cell lung cancer Bristol-Myers Squibb Services Unlimited Company
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 Phase III Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia … F. Hoffmann-La Roche AG
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 Phase III Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations Taiho Oncology Inc.
• An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi… Recruiting
  2024-512714-18-00 Phase I/II Relapsing Multiple Sclerosis Novartis Pharma AG
• Randomized phase 2 study of Simvastatin in patients with ARID1A mutated advanced gastrooesophageal carcinoma treated with Nivolumab and Oxal… Recruiting
  2024-519591-39-00 Phase II advanced or metastatic gastrooesophageal carcinoma HER2 nega… IRCCS Istituto Nazionale Tumori Fondazione Pascale
• A study evaluating persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccinatio… Recruiting
  2024-519730-23-00 Phase II Respiratory Syncytial Virus Infections GlaxoSmithKline Biologicals
• The IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients wi… Recruiting
  2024-514879-17-00 Phase III Gastric cancer Karolinska University Hospital
• A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immuno… Recruiting
  2023-507115-35-00 Phase III Chronic Immune Thrombocytopenia (ITP) Kedrion S.p.A.
• A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant… Recruiting
  2024-516794-70-00 Phase II Metastatic non-squamous non-small cell lung cancer CatalYm GmbH
• Study to assess the pharmacokinetics, safety, and tolerability of iptacopan in pediatric PNH patients Recruiting
  2024-515926-10-00 Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis Pharma AG
• A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibit… Recruiting
  2025-521088-10-00 Phase II Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)… Nurix Therapeutics Inc.
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec… Recruiting
  2025-520582-51-00 Phase III Hormone receptor positive breast cancer Merck Sharp & Dohme LLC
• Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting
  2023-508804-39-00 Phase III Ulcerative Colitis or Crohn’s Disease Takeda Development Center Americas Inc.
• The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease Recruiting
  2024-518645-17-00 Phase III Blood and lymphatic diseases Sanofi-Aventis Recherche & Developpement
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 Phase III Major Depressive Disorder Neurocrine Biosciences Inc.
• A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th… Recruiting
  2025-521055-23-00 Phase II/III Chronic Idiopathic thrombocytopenic purpura Argenx
• A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520259-26-00 Phase III Mania or Mania with Mixed Features in Bipolar-I Disorder Bristol-Myers Squibb Services Unlimited Company

Showing 481–504 of 3,684 trials